Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6372MR)

This product GTTS-WQ6372MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6372MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7445MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ8867MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ9765MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ14522MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ10846MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ10376MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ5858MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ5474MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDB-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW